Investing.com - AbbVie (NYSE: ABBV) reported third quarter EPS of $2.95, $0.08 better than the analyst estimate of $2.87. Revenue for the quarter came in at $13.93B versus the consensus estimate of $13.71B.
Guidance
AbbVie sees Q4 2023 EPS of $11.19-$11.23 versus the analyst consensus of $11.06.
AbbVie's stock price closed at $145.20. It is down -3.75% in the last 3 months and down -1.63% in the last 12 months.
AbbVie saw 10 positive EPS revisions and 5 negative EPS revisions in the last 90 days. See AbbVie's stock price’s past reactions to earnings here.
According to InvestingPro, AbbVie's Financial Health score is "great performance".
Check out AbbVie's recent earnings performance, and AbbVie's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar